Ayotunde J Fasunla1, Nadia Harbeck2, Barbara Schmalfeld3, Sabina Berktold3, Christina Böhner3, Walter Hundt4, Petra Wolf5, Silke Steinbach6. 1. Department of Otorhinolaryngology, Philipps-University, Marburg, Germany ; Department of Otorhinolaryngology, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria, Germany. 2. Breast Centre, Ludwig-Maximilians University, Munich, Germany. 3. Department of Obstetrics and Gynaecology, Women's Hospital Rechts der Isar, Germany. 4. Department of Radiology, Philipps-University, Marburg, Germany. 5. Institute of Medical Statistics and Epidemiology, Hospital Rechts der Isar, Technical University Munich, Germany. 6. Department of Otorhinolaryngology, Philipps-University, Marburg, Germany.
Abstract
BACKGROUND: Our objective was to assess the auditory function of gynaecological tumour patients who had received cytotoxic agents and to determine their associated risk of ototoxicity. PATIENTS AND METHODS: 87 patients who had undergone chemotherapy for gynaecological malignancies were investigated. Of these patients, 79% had breast cancer, and 14% ovarian cancer. All of the patients had a subjective assessment of their hearing function on a visual analogue scale. Audiometric tests were performed before and at 9 weeks, 18 weeks and 3 months after completion of chemotherapy. RESULTS: The age of the patients ranged from 32 to 71 years (mean age of 53.5 ± 10.5 years). The average subjective rating of the patients' hearing function was 83.0 ± 17.2 before and 84.8 ± 16.9 3 months after completion of chemotherapy. No significant audiometric change at either the speech hearing frequency range (0.5-2 KHz) or high frequencies was observed in the patients after chemotherapy. There was also no significant difference in the hearing threshold of the patients who had received platinum analogue-based chemotherapy compared to non-platinum analogue-based chemotherapy. CONCLUSION: Hearing loss is uncommon in patients treated with the typical gynaecological chemotherapy protocols. Hence, routine audiometric testing in these patients is not necessary.
BACKGROUND: Our objective was to assess the auditory function of gynaecological tumourpatients who had received cytotoxic agents and to determine their associated risk of ototoxicity. PATIENTS AND METHODS: 87 patients who had undergone chemotherapy for gynaecological malignancies were investigated. Of these patients, 79% had breast cancer, and 14% ovarian cancer. All of the patients had a subjective assessment of their hearing function on a visual analogue scale. Audiometric tests were performed before and at 9 weeks, 18 weeks and 3 months after completion of chemotherapy. RESULTS: The age of the patients ranged from 32 to 71 years (mean age of 53.5 ± 10.5 years). The average subjective rating of the patients' hearing function was 83.0 ± 17.2 before and 84.8 ± 16.9 3 months after completion of chemotherapy. No significant audiometric change at either the speech hearing frequency range (0.5-2 KHz) or high frequencies was observed in the patients after chemotherapy. There was also no significant difference in the hearing threshold of the patients who had received platinum analogue-based chemotherapy compared to non-platinum analogue-based chemotherapy. CONCLUSION: Hearing loss is uncommon in patients treated with the typical gynaecological chemotherapy protocols. Hence, routine audiometric testing in these patients is not necessary.
Entities:
Keywords:
Breast cancer; Chemotherapy; Hearing function; Ovarian cancer
Authors: C L Zuur; Y J W Simis; P E M Lansdaal; C R N Rasch; R A Tange; A J M Balm; W A Dreschler Journal: Audiol Neurootol Date: 2006-09-18 Impact factor: 1.854
Authors: A D R Huitema; M Spaander; R A A Mathĵt; M M Tibben; M J Holtkamp; J H Beijnen; S Rodenhuis Journal: Ann Oncol Date: 2002-03 Impact factor: 32.976
Authors: Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; Nico van Zandwijk; Jan H M Schellens Journal: J Clin Oncol Date: 2006-02-20 Impact factor: 44.544